Reviewing Metabolix (YTEN) & ImmunoGen (IMGN)
Metabolix (NASDAQ: YTEN) and ImmunoGen (NASDAQ:IMGN) are both consumer staples companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.
This table compares Metabolix and ImmunoGen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
9.2% of Metabolix shares are owned by institutional investors. Comparatively, 73.0% of ImmunoGen shares are owned by institutional investors. 11.2% of Metabolix shares are owned by insiders. Comparatively, 6.5% of ImmunoGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Metabolix and ImmunoGen’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
Metabolix has higher revenue, but lower earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Metabolix, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and target prices for Metabolix and ImmunoGen, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Given ImmunoGen’s higher probable upside, analysts clearly believe ImmunoGen is more favorable than Metabolix.
Risk and Volatility
Metabolix has a beta of 3.54, suggesting that its stock price is 254% more volatile than the S&P 500. Comparatively, ImmunoGen has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500.
ImmunoGen beats Metabolix on 7 of the 10 factors compared between the two stocks.
Metabolix Company Profile
Yield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.
ImmunoGen Company Profile
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
Receive News & Stock Ratings for Metabolix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metabolix Inc. and related stocks with our FREE daily email newsletter.